Skip to main content
FDA Shortage Check

Is Relexxii (Methylphenidate Hydrochloride Tablet, Extended Release) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Relexxii: in shortage (FDA, Oct 24)

Extended- & delayed-release tablets
A generic extended-release tablet, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Demand increase for the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Discontinuation of the manufacture of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated recovery: November 2026”. Manufacturer’s estimate, Lannett Company, Inc., Oct 15, 2026
DRUG
Relexxii
FDA LISTING
FORM
ER tablets
STATUS
Currently in Shortage
FIRST POSTED
Jul 26, 2023
LAST FDA UPDATE
Oct 20, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 34 presentations: 6 unavailable · 9 limited · 19 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Methylphenidate Hydrochloride Tablet, Extended Release. 34 presentations from 6 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Lannett Company, Inc.4 presentations · 2 unavailable · 2 available or not stated

Contact (FDA's listing): 844-834-0530

  • 27 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)

    Estimated recovery: November 2026

    NDC 62175-311-37Reverified

    Unavailable

  • 36 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)

    Estimated recovery: November 2026

    NDC 62175-312-37Reverified

    Unavailable

  • 18 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)

    NDC 62175-310-37Reverified

    Available

  • 54 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)

    NDC 62175-313-37Reverified

    Available

Sun Pharmaceutical Industries, Inc.4 presentations · 4 unavailable

Contact (FDA's listing): 800-818-4555

  • 18 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)

    Currently not marketed

    NDC 57664-606-88Reverified

    Unavailable

  • 27 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)

    Currently not marketed

    NDC 57664-607-88Reverified

    Unavailable

  • 36 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)

    Currently not marketed

    NDC 57664-608-88Reverified

    Unavailable

  • 54 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)

    Currently not marketed

    NDC 57664-609-88Reverified

    Unavailable

Teva Pharmaceuticals USA, Inc.4 presentations · 2 limited · 2 available or not stated

Contact (FDA's listing): 800-545-8800

  • 27 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)

    Estimated recovery: October 2026

    NDC 62037-734-01Revised

    Limited Availability

  • 36 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)

    Estimated recovery: October 2026

    NDC 62037-726-01Reverified

    Limited Availability

  • 18 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)

    NDC 62037-725-01Revised

    Available

  • 54 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)

    NDC 62037-727-01Reverified

    Available

Trigen Laboratories, LLC7 presentations · 7 limited

Contact (FDA's listing): 800-541-4802

  • 18 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)

    Allocation to current contracted customers

    NDC 13811-706-10Reverified

    Limited Availability

  • 27 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)

    Allocation to current contracted customers

    NDC 13811-707-10Reverified

    Limited Availability

  • 36 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)

    Allocation to current contracted customers

    NDC 13811-708-10Reverified

    Limited Availability

  • 45 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)

    Allocation to current contracted customers

    NDC 13811-711-30Reverified

    Limited Availability

  • 54 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)

    Allocation to current contracted customers

    NDC 13811-709-10Reverified

    Limited Availability

  • 63 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)

    Allocation to current contracted customers

    NDC 13811-700-30Reverified

    Limited Availability

  • 72 mg

    Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)

    Allocation to current contracted customers

    NDC 13811-710-30Reverified

    Limited Availability

Janssen Pharmaceuticals4 presentations · 4 available or not stated

Contact (FDA's listing): 800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET

  • 18 mg

    Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)

    NDC 50458-585-01Reverified

    Available

  • 27 mg

    Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)

    NDC 50458-588-01Reverified

    Available

  • 36 mg

    Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)

    NDC 50458-586-01Reverified

    Available

  • 54 mg

    Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)

    NDC 50458-587-01Reverified

    Available

Vertical Pharmaceuticals, LLC11 presentations · 11 available or not stated

Contact (FDA's listing): 800-541-4802

  • 18 mg

    Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)

    NDC 68025-095-10Reverified

    Available

  • 18 mg

    Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)

    NDC 68025-095-30Reverified

    Available

  • 27 mg

    Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)

    NDC 68025-096-10Reverified

    Available

  • 27 mg

    Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)

    NDC 68025-096-30Reverified

    Available

  • 36 mg

    Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)

    NDC 68025-097-10Reverified

    Available

  • 36 mg

    Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)

    NDC 68025-097-30Reverified

    Available

  • 45 mg

    Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)

    NDC 68025-088-30Reverified

    Available

  • 54 mg

    Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)

    NDC 68025-098-10Reverified

    Available

  • 54 mg

    Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)

    NDC 68025-098-30Reverified

    Available

  • 63 mg

    Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)

    NDC 68025-089-30Reverified

    Available

  • 72 mg

    Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)

    NDC 68025-084-30Reverified

    Available

What the manufacturers told FDA

  • Lannett Company, Inc. · ‘Estimated recovery: November 2026’ · updated Oct 2026
  • Teva Pharmaceuticals USA, Inc. · ‘Estimated recovery: October 2026’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Demand increase for the drug
  • Discontinuation of the manufacture of the drug
  • Other

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Shown as FDA status, not as suggestions.

Same active ingredient, other salts or forms

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Relexxii in shortage?
Yes. As of Oct 24, 2026, FDA lists Methylphenidate Hydrochloride Tablet, Extended Release as currently in shortage: 34 presentations, 6 unavailable and 9 limited.
When will the Relexxii shortage end?
FDA gives no end date. 4 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Relexxii?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.